Calypso Medical Technologies is revolutionizing radiation therapy with its proprietary tumor localization system, utilizing miniaturized implanted devices called Beacon® electromagnetic transponders to continuously and accurately track tumor locations. This breakthrough technology, which has received FDA 510(k) clearance for use in the prostate and post-operative prostatic bed, enhances the precision and management of radiation therapy for various cancers.
Founded in 1999 and based in Seattle, the company specializes in medical devices and has established strategic partnerships with industry leaders including Varian Medical Systems, Siemens Medical Systems, Elekta Corporation, and Philips Medical.
The latest investment of $7.50M in Debt Financing was secured on 04 March 2011. Calypso Medical Technologies' groundbreaking approach to tumor tracking and precision in radiation therapy positions it as a promising player in the Health Care and Medical Devices industries.
